+1 (704) 266-3234

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Review H1 2018

Published on: May 2018 | From USD $2000 | Published By: GMD | Number Of Pages: 390

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 15, 11, 2, 71, 32 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 30 and 24 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 6
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview 7
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development 8
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment 38
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development 48
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles 82
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects 346
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products 358
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones 359
Appendix 370

List of Tables
Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AbbVie Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Pharmaceuticals Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corp, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Antibiotx ApS, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corp, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Atriva Therapeutics GmbH, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3J Therapeutics Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cadila Pharmaceuticals Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corp, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helperby Therapeutics Group Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Insmed Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Instituto Biomar SA, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by KBP BioSciences Co Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lakewood-Amedex Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lead Discovery Center GmbH, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics BV, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals Inc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics plc, H1 2018
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience Inc, H1 2018

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $2000
USD $4000
USD $6000
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.